NCT02430714已完成不适用
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 629
- 主要终点
- Number of participants with adverse events (AEs)/adverse drug reactions (ADRs)
研究概览
简要总结
This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants with unresectable thyroid cancer and administrated Lenvatinib.
排除标准
- 未提供
研究组 & 干预措施
Arm 1
A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
干预措施: Lenvatinib (Drug)
结局指标
主要结局
Number of participants with adverse events (AEs)/adverse drug reactions (ADRs)
时间窗: up to 1 year
次要结局
- Overall survival (OS)(up to 1 year)
研究者
相似试验
已完成
不适用
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine PracticeRenal Cell CarcinomaNCT02533258Pfizer13
已完成
不适用
A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsEndometrial NeoplasmsEndometriumCarcinomaRenal Cell CarcinomaNCT05375136Eisai Korea Inc.135
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerThyroid NeoplasmsNCT03573960Eisai Pharmaceuticals India Pvt. Ltd50
已完成
不适用
ULTIVA Post Marketing SurveillanceAnalgesiaNCT01299584GlaxoSmithKline775
招募中
不适用
Retrospective study for Lenvatinib for unresectable thyroid cancersnresectable thyroid cacersJPRN-UMIN000030969Kyoto Prefectural University of Medicine50